Adverse events recorded before and after tocilizumab start.
| Adverse Event | Preinclusion, Median Follow-up 511 days (IQR 143–1292) | Postinclusion, Median Follow-up 842 days (IQR 568–1434) |
|---|---|---|
| Corticotropin deficiency | 0 (0) | 10 (23) |
| Hypertension | 10 (23) | 6 (14) |
| Diabetes | 11 (26) | 3 (7) |
| Central obesity | 18 (42) | 1 (2) |
| Myopathy | 9 (21) | 3 (7) |
| Osteoporotic fracture | 3 (7) | 10 (23) |
| Osteonecrosis | 1 (2) | 1 (2) |
| Peptic ulcer | 2 (5) | 0 (0) |
| Mood change | 17 (40) | 1 (2) |
| Cataract | 7 (16) | 4 (9) |
| Cardiovascular event | 1 (2) | 1 (2) |
| Infection | 15 (35) | 29 (67) |
| Severe infection | 3 (7) | 8 (19) |
| Neutropenia | 0 (0) | 10 (23) |
| Grade I/II | 0 (0) | 8 |
| Grade III/IV | 0 (0) | 2 |
| Thrombocytopenia | 0 (0) | 6 (14) |
| Aminotransferase increase | 0 (0) | 2 (5) |
| Other | 0 (0) | 8 (19) |
| Headache | 0 (0) | 2 |
| Digestive disorder | 0 (0) | 2 |
| Cutaneous vasculitis | 0 (0) | 2 |
| Renal cell carcinoma | 0 (0) | 1 |
| Aphthous ulcers | 0 (0) | 1 |